“Today we announced that we have submitted to the US Food and Drug Administration an application for Emergency Use Authorization (EUA) of our Omicron BA.4/BA.5 bivalent adapted COVID-19 vaccine in children aged between 6 months and 4 years”. This is what the companies Pfizer and BioNTech communicate, explaining that the request for ok concerns the use of the updated vaccine as a third dose of 3 micrograms in the three-dose primary cycle envisaged for the little ones.
“With the high level of respiratory diseases currently circulating among children under 5 years of age, updated Covid vaccines can help prevent serious illness and hospitalization,” note the two American and German companies. If cleared by the regulatory body, “children in this age group would receive a primary series consisting of two 3 μg doses of Pfizer-BioNTech’s original Covid vaccine, followed by a third 3 μg dose.” of the Omicron BA.4/BA.5 vaccine.
